Wirth LJ, et al. Registrational results of LIBRETTO-001: A phase 1/2 trial of selpercatinib (LOXO-292) in patients with RET-altered thyroid cancers. ESMO Congress 2019. Abstract LBA93. 29 sept, Barcelona, Spanje.
Synergetisch effect van radiotherapie + immuuntherapie bij NSCLC
mei 2021 | Immuuntherapie, Longoncologie, Radiotherapie